GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019
Epidiolex U.S. reported a Q1 net sales of $33.5m.
Read More
Category: UK Stocks
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).
Read More
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting
The community has warmly received the launch of Epidiolex, the first prescription pharmaceutical formulation of highly purified CBD in the U.S. for seizures associated with LGS or Dravet syndrome.
Read More
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending March 31, 2019 and Host Conference Call on May 6, 2019
Conference call information will be provided in the financial results press release.
Read More
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercial Officer
Mr. Cline is an accomplished biopharmaceutical executive with over 25 years of commercial experience and was previously Executive Vice President, Commercial and a member of the Executive Committee at Seattle Genetics, where he oversaw all marketing, sales, and managed markets functions.
Read MoreGET LISTED
